Literature DB >> 19941779

Surveillance of the first 205 confirmed hospitalised cases of pandemic H1N1 influenza in Ireland, 28 April - 3 October 2009.

G Cullen1, J Martin, J O'Donnell, M Boland, M Canny, E Keane, A McNamara, A O'Hora, M Fitzgerald, S Jackson, D Igoe, D O'Flanagan.   

Abstract

From 28 April 2009 to 3 October 2009, 205 cases of confirmed pandemic H1N1 influenza were hospitalised in Ireland. Detailed case-based epidemiological information was gathered on all hospitalised cases. Age-specific hospitalisation rates were highest in the age group of 15 to 19 year-olds and lowest in those aged 65 years and over. Nineteen hospitalised cases (9%) were admitted to intensive care units (ICU) where the median length of stay was 24 days. Four hospitalised cases (2%) died. Fifty-one percent of hospitalised cases and 42% of ICU cases were not in a recognised risk group. Asthma was the most common risk factor among cases; however, people with haemoglobinopathies and immunosuppression were the most over-represented groups.

Entities:  

Mesh:

Year:  2009        PMID: 19941779

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  30 in total

1.  Epidemiological aspects of pandemic influenza A(H1N1) virus from 2009 to 2011 in Iran.

Authors:  Jila Yavarian; Maryam Naseri; Azadeh Shadab; Nazanin Z Shafiei Jandaghi; Talat Mokhtari Azad
Journal:  Influenza Other Respir Viruses       Date:  2012-04-06       Impact factor: 4.380

2.  Pandemic influenza A(H1)pdm09 in hospitals and intensive care units - results from a new hospital surveillance, Germany 2009/2010.

Authors:  Cornelia Adlhoch; Maria Wadl; Michael Behnke; Luis Alberto Peña Diaz; Jörg Clausmeyer; Tim Eckmanns
Journal:  Influenza Other Respir Viruses       Date:  2012-07-13       Impact factor: 4.380

Review 3.  Influenza susceptibility, severity, and shedding in HIV-infected adults: a review of the literature.

Authors:  Anandi N Sheth; Keri N Althoff; John T Brooks
Journal:  Clin Infect Dis       Date:  2011-01-15       Impact factor: 9.079

Review 4.  Epidemiological aspects of 2009 H1N1 influenza: the accumulating experience from the Northern Hemisphere.

Authors:  M E Falagas; N V Cholevas; A M Kapaskelis; E K Vouloumanou; A Michalopoulos; P I Rafailidis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-07-13       Impact factor: 3.267

5.  Relationship between respiratory viral load and lung lesion severity: a study in 24 cases of pandemic H1N1 2009 influenza A pneumonia.

Authors:  Pu-Xuan Lu; Ying-Ying Deng; Gui-Lin Yang; Wei-Long Liu; Ying-Xia Liu; Hua Huang; Yi-Xiang J Wang
Journal:  J Thorac Dis       Date:  2012-08       Impact factor: 2.895

Review 6.  Two years after pandemic influenza A/2009/H1N1: what have we learned?

Authors:  Vincent C C Cheng; Kelvin K W To; Herman Tse; Ivan F N Hung; Kwok-Yung Yuen
Journal:  Clin Microbiol Rev       Date:  2012-04       Impact factor: 26.132

7.  Registry-based surveillance of influenza-associated hospitalisations during the 2009 influenza pandemic in Denmark: the hidden burden on the young.

Authors:  Katarina Widgren; Jens Nielsen; Kåre Mølbak
Journal:  PLoS One       Date:  2010-11-11       Impact factor: 3.240

8.  The challenges of global case reporting during pandemic A(H1N1) 2009.

Authors:  Stephanie Williams; Julia Fitzner; Angela Merianos; Anthony Mounts
Journal:  Bull World Health Organ       Date:  2013-08-23       Impact factor: 9.408

9.  Asthma in patients hospitalized with pandemic influenza A(H1N1)pdm09 virus infection-United States, 2009.

Authors:  John J McKenna; Anna M Bramley; Jacek Skarbinski; Alicia M Fry; Lyn Finelli; Seema Jain
Journal:  BMC Infect Dis       Date:  2013-01-31       Impact factor: 3.090

10.  Differences between asthmatics and nonasthmatics hospitalised with influenza A infection.

Authors:  Puja Myles; Jonathan S Nguyen-Van-Tam; Malcolm G Semple; Stephen J Brett; Barbara Bannister; Robert C Read; Bruce L Taylor; Jim McMenamin; Joanne E Enstone; Karl G Nicholson; Peter J Openshaw; Wei Shen Lim
Journal:  Eur Respir J       Date:  2012-08-16       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.